search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Therapeutics


development of EV-mediated therapies is a grow- ing market segment, with a number of start-up and more established companies moving forward in this field. Most of the recent advances in EV research are technology-driven and particularly linked to high sensitivity imaging capabilities, such as single-molecule localisation microscopy. This enables quantification of EV cargoes and subtypes, and tracking of EV dynamics with unprecedented precision, helping to better understand their com- position and uptake mechanisms by living cells. Overall, the combination of established methods


and emerging disruptive technologies is progres- sively allowing the more precise characterisation of EV therapies and understanding of their mecha- nism of action, helping to modulate drug dosage and delivery and bringing to light more efficient treatments for hard-to-treat conditions such as cancer and neurodegenerative diseases.


DDW


Dr Anna Caballe has a PhD in Molecular and Cell Biology and applied super-resolution microscopy during her postdoctoral research at the University of Oxford. Anna joined ONI as a Grant Writer in March 2019, working


across Business


Development and Marketing, driving grant pro- posals for the development of new products and applications using ONI’s technology and expand- ing her role into Product Management.


Dr Katarzyna Ginda-Mäkelä trained in super-res- olution microscopy at


the Biochemistry


Department, University of Oxford, before joining ONI as Application Scientist. Currently her role is focused on product marketing management and content generation for various marketing channels.


Drug Discovery World Winter 2019/20 31


References 1 Kornilov et al. Efficient ultrafiltration-based protocol to deplete extracellular vesicles from fetal bovine serum. J Extracell Vesicles (2018) 7(1): 1422674. 2 Margolis, L and Sadovsky, Y. The biology of extracellular vesicles: The known unknowns. PLoS Biol (2019) 18; 17(7):e3000363. 3Théry, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles (2018) 23; 7(1):1535750. 4 Roy, S, Hochberg, FH and Jones, PS. Extracellular vesicles: the growth as diagnostics and therapeutics; a survey. J Extracell Vesicles (2018) 7(1): 1438720. 5 Exosome Diagnostics and Therapeutics Market 2019 Global Analysis, Opportunities And Forecast To 2024 (2019). Medgadget: https://www. medgadget.com/2019/09/exoso me-diagnostics-and- therapeutics-market-2019- global-analysis-opportunities- and-forecast-to-2024.html. 6 Exosome Diagnostic and Therapeutic Market Overview, Global Opportunity Analysis and Industry Forecasts, 2014- 2022 (2016) Allied Market Research: https://www. alliedmarketresearch.com/exos ome-diagnostic-and- therapeutic-market


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68